Compare GPMT & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPMT | CLRB |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5M | 24.5M |
| IPO Year | 2017 | 2008 |
| Metric | GPMT | CLRB |
|---|---|---|
| Price | $3.33 | $1.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $11.50 | $11.50 |
| AVG Volume (30 Days) | 43.1K | ★ 159.7K |
| Earning Date | 11-04-2026 | 11-10-2026 |
| Dividend Yield | ★ 10.72% | N/A |
| EPS Growth | ★ 73.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $308.40 | N/A |
| Revenue Next Year | $9.66 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.74 | $1.12 |
| 52 Week High | $7.61 | $4.70 |
| Indicator | GPMT | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 40.14 | 39.39 |
| Support Level | $1.39 | N/A |
| Resistance Level | $7.61 | $3.40 |
| Average True Range (ATR) | 0.34 | 0.10 |
| MACD | -0.28 | 0.04 |
| Stochastic Oscillator | 0.85 | 50.00 |
Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the commercial property.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.